Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000156401 | SCV000206119 | uncertain significance | not specified | 2014-03-19 | criteria provided, single submitter | clinical testing | The Val658Ala variant in VCL has not been previously reported in individuals wit h cardiomyopathy or in large population studies. Computational prediction tools and conservation analysis do not provide strong support for or against an impact to the protein. Additional information is needed to fully assess the clinical s ignificance of the variant. |
Genetics and Genomics Program, |
RCV001293164 | SCV001434161 | uncertain significance | Primary dilated cardiomyopathy | criteria provided, single submitter | research | ||
Labcorp Genetics |
RCV001470512 | SCV001674608 | likely benign | Dilated cardiomyopathy 1W | 2023-12-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001559741 | SCV001782032 | likely benign | not provided | 2018-07-05 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 26191084) |
Ambry Genetics | RCV002415675 | SCV002721364 | likely benign | Cardiovascular phenotype | 2020-07-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |